CRISPR Therapeutics (NASDAQ:CRSP) Receives Buy Rating from Chardan Capital

Chardan Capital reissued their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP - Free Report) in a research note released on Thursday,Benzinga reports. Chardan Capital currently has a $82.00 price objective on the stock.

A number of other research analysts have also issued reports on CRSP. JMP Securities reiterated a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, May 21st. Barclays decreased their price target on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research report on Friday, May 9th. Wall Street Zen upgraded shares of CRISPR Therapeutics to a "sell" rating in a research report on Friday, May 16th. Needham & Company LLC restated a "buy" rating and issued a $81.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, May 20th. Finally, The Goldman Sachs Group decreased their price target on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $71.75.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock traded up $0.79 during midday trading on Thursday, reaching $47.49. 15,070,469 shares of the company's stock traded hands, compared to its average volume of 1,857,545. The company has a market cap of $4.10 billion, a price-to-earnings ratio of -10.51 and a beta of 1.75. The company's 50 day simple moving average is $39.48 and its 200 day simple moving average is $40.50. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $63.68.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. During the same quarter last year, the business earned ($1.43) earnings per share. The business's revenue for the quarter was up 71.6% on a year-over-year basis. As a group, equities research analysts predict that CRISPR Therapeutics will post -5.16 earnings per share for the current year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the business's stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the transaction, the insider now directly owns 6,068 shares of the company's stock, valued at approximately $218,083.92. The trade was a 39.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Intellectus Partners LLC raised its stake in shares of CRISPR Therapeutics by 3.6% during the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock worth $281,000 after buying an additional 250 shares during the last quarter. Farrow Financial Inc. raised its stake in shares of CRISPR Therapeutics by 1.4% during the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock worth $777,000 after buying an additional 270 shares during the last quarter. SFE Investment Counsel raised its stake in shares of CRISPR Therapeutics by 5.8% during the first quarter. SFE Investment Counsel now owns 6,507 shares of the company's stock worth $221,000 after buying an additional 355 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of CRISPR Therapeutics by 7.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company's stock worth $215,000 after buying an additional 372 shares during the last quarter. Finally, Axxcess Wealth Management LLC raised its stake in shares of CRISPR Therapeutics by 4.0% during the first quarter. Axxcess Wealth Management LLC now owns 10,309 shares of the company's stock worth $351,000 after buying an additional 393 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.